VA-MENGOC-BC®

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
VA-MENGOC-BC®
Accession Number
DB15800
Description

VA-MENGOC-BC is a meningococcal B and C vaccine and an outer membrane vesicle (OMV)-based vaccine. The OMVs contain over 100 proteins, and are derived from meningococcal group B and capsular polysaccharide of meningococcal group C. As there already exists a polysaccharide-based vaccine against meningococcal disease originating from serogroups A,C,W135, and Y, this vaccine was created for use against serogroups B and C. This vaccine causes induction of bactericidal antibodies with broad cross-reactivity. Novel antigens such as γ-glutamyltranspeptidase, exopolyphosphatase, and a cell-binding factor protein were also identified with administration of this vaccine by a study. This vaccine may also induce moderate protection against N. gonorrhoeae. As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.

Type
Biotech
Groups
Investigational
Synonyms
  • Meningococcal polysaccharide vaccine groups B and C
External IDs
  • VA-MENGOC-BC

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Ochoa-Azze RF: Cross-protection induced by VA-MENGOC-BC(R) vaccine. Hum Vaccin Immunother. 2018 May 4;14(5):1064-1068. doi: 10.1080/21645515.2018.1438028. Epub 2018 Feb 26. [PubMed:29420119]
  2. Sierra-Gonzalez VG: Cuban Meningococcal Vaccine VA-MENGOC-BC:30 Years of Use and Future Potential. MEDICC Rev. 2019 Oct;21(4):19-27. [PubMed:32335565]
  3. Ochoa-Azze RF, Garcia-Imia L, Verez-Bencomo V: Effectiveness of a Serogroup B and C Meningococcal Vaccine Developed in Cuba. MEDICC Rev. 2018 Jul;20(3):22-29. [PubMed:31242158]
  4. Uli L, Castellanos-Serra L, Betancourt L, Dominguez F, Barbera R, Sotolongo F, Guillen G, Pajon Feyt R: Outer membrane vesicles of the VA-MENGOC-BC vaccine against serogroup B of Neisseria meningitidis: Analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry. Proteomics. 2006 Jun;6(11):3389-99. doi: 10.1002/pmic.200500502. [PubMed:16673438]
  5. VA-MENGOC-BC Information [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on September 05, 2020 16:29 / Updated on September 13, 2020 03:35